Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
作者信息
Komrokji Rami S, Aguirre Luis E, Al Ali Najla H, Chan Onyee, Xie Zhuoer, Kuykendall Andrew, Sweet Kendra, Lancet Jeffrey E, Padron Eric, Sallman David A
机构信息
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
出版信息
Blood Adv. 2023 Jul 25;7(14):3677-3679. doi: 10.1182/bloodadvances.2023009781.
Abstract
摘要
相似文献
1
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
Blood Adv. 2023 Jul 25;7(14):3677-3679. doi: 10.1182/bloodadvances.2023009781.
2
Luspatercept in Myelodysplastic Syndromes: Who and When?
Hematol Oncol Clin North Am. 2020 Apr;34(2):393-400. doi: 10.1016/j.hoc.2019.10.004. Epub 2020 Jan 21.
3
Luspatercept: First Approval.
Drugs. 2020 Jan;80(1):85-90. doi: 10.1007/s40265-019-01251-5.
4
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough.
Am J Hematol. 2023 Aug;98(8):1171-1175. doi: 10.1002/ajh.27003. Epub 2023 Jun 22.
5
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Expert Opin Biol Ther. 2024 Apr;24(4):233-241. doi: 10.1080/14712598.2024.2336086. Epub 2024 Mar 30.
6
Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
Leuk Res. 2020 Oct;97:106430. doi: 10.1016/j.leukres.2020.106430. Epub 2020 Jul 30.
7
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.
8
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
9
Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Future Oncol. 2021 Apr;17(12):1473-1481. doi: 10.2217/fon-2020-1093. Epub 2021 Jan 29.
10
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):395-404. doi: 10.1002/psp4.12521. Epub 2020 Jun 30.
引用本文的文献
1
Advances and challenges in the treatment of myelodysplastic syndromes.
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
2
How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome.
Br J Haematol. 2025 Jul;207(1):15-26. doi: 10.1111/bjh.20126. Epub 2025 May 2.
3
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.
Hemasphere. 2025 Feb 12;9(2):e70086. doi: 10.1002/hem3.70086. eCollection 2025 Feb.
4
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Curr Treat Options Oncol. 2024 Jun;25(6):752-768. doi: 10.1007/s11864-024-01217-0. Epub 2024 May 30.
本文引用的文献
1
Myelodysplastic Syndromes: A New Decade.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):1-16. doi: 10.1016/j.clml.2021.07.031. Epub 2021 Aug 2.
2
Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
J Clin Invest. 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678.
3
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
4
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
Curr Hematol Malig Rep. 2019 Aug;14(4):346-351. doi: 10.1007/s11899-019-00517-9.
5
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Br J Haematol. 2019 Jan;184(2):134-160. doi: 10.1111/bjh.15707. Epub 2018 Dec 13.
6
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Br J Haematol. 2003 Mar;120(6):1037-46. doi: 10.1046/j.1365-2141.2003.04153.x.
Zotero 插件